دورية أكاديمية
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
| العنوان: | Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies |
|---|---|
| المؤلفون: | Bruel, Timothée, Stéfic, Karl, Nguyen, Yann, Toniutti, Donatella, Staropoli, Isabelle, Porrot, Françoise, Guivel-Benhassine, Florence, Bolland, William-Henry, Planas, Delphine, Hadjadj, Jérôme, Handala, Lynda, Planchais, Cyril, Prot, Matthieu, Simon-Lorière, Etienne, André, Emmanuel, Baele, Guy, Cuypers, Lize, Mouthon, Luc, Mouquet, Hugo, Buchrieser, Julian, Sève, Aymeric, Prazuck, Thierry, Maes, Piet, Terrier, Benjamin, Hocqueloux, Laurent, Schwartz, Olivier |
| المساهمون: | Virus et Immunité - Virus and immunity (CNRS-UMR3569), Institut Pasteur Paris (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Vaccine Research Institute Créteil, France (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Morphogénèse et antigénicité du VIH, des Virus des Hépatites et Emergents (MAVIVHe), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Référence du VIH Tours - laboratoire associé (CNR VIH), Centre de référence des maladies auto-immunes systémiques rares d'Île-de-France / National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), École Doctorale Bio Sorbonne Paris Cité Paris (ED562 - BioSPC), Université Sorbonne Paris Cité (USPC)-Université Paris Cité (UPCité), Immunologie humorale - Humoral Immunology, Institut Pasteur Paris (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses, Institut Pasteur Paris (IP)-Université Paris Cité (UPCité), University Hospitals Leuven Leuven, Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven), Centre Hospitalier Régional d'Orléans (CHRO), Work in the O.S. lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Médicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, and ANR Coronamito and IDISCOVR. Work in the UPBI facility is funded by grant ANR-10-INSB-04-01 and the Région Ȋle-de-France program DIM1Health. D.P. is supported by the Vaccine Research Institute. P.M. acknowledges the support of a COVID-19 research grant from “Fonds Wetenschappelijk Onderzoek” /Research Foundation Flanders (grant G0H4420N) and “Internal Funds KU Leuven” (grant 3M170314). E.S.-L. acknowledges funding from the INCEPTION program (Investissements d’Avenir grant ANR-16-CONV-0005)., We thank the European Health Emergency Preparedness and Response Authority (HERA) for supporting the work being done at Institut Pasteur and UK Leuven. We thank the patients who participated in this study. We thank members of the Virus and Immunity Unit for discussions and help. We thank Ludivine Grzelak for her help in creating an illustration of SARS-CoV-2 variant mutations. We thank N. Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis. The Opera system was co-funded by Institut Pasteur and the Région Ȋle-de-France (DIM1Health). We thank F. Peira, V. Legros, and L. Courtellemont for their help with the cohorts. UZ Leuven, as a national reference center for respiratory pathogens, is supported by Sciensano, which is gratefully acknowledged. We thank Hélène Péré and David Veyer for their help in sequencing viral strains and helpful discussions., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-10-LABX-0077,VRI,Initiative for the creation of a Vaccine Research Institute(2010), ANR-20-COVI-0059,PROTEO-SARS-CoV-2,Protéomique du SARS-CoV-2(2020), ANR-21-CO14-0007,CoronaMito,Conséquences de l'infection par le SRAS-CoV-2 sur la fonction mitochondriale(2021), ANR-16-CONV-0005,INCEPTION,Institut Convergences pour l'étude de l'Emergence des Pathologies au Travers des Individus et des populatiONs(2016) |
| المصدر: | ISSN: 2666-3791 ; Cell Reports Medicine ; https://pasteur.hal.science/pasteur-04165260Test ; Cell Reports Medicine, 2022, 3 (12), pp.100850. ⟨10.1016/j.xcrm.2022.100850⟩. |
| بيانات النشر: | HAL CCSD Cell Press |
| سنة النشر: | 2022 |
| المجموعة: | Université François-Rabelais de Tours: HAL |
| مصطلحات موضوعية: | ADCC, Omicron, SARS-CoV-2, antibodies, neutralization, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy |
| الوصف: | International audience ; The emergence of Omicron sublineages impacts the therapeutic efficacy of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs). Here, we evaluate neutralization and antibody-dependent cellular cytotoxicity (ADCC) activities of 6 therapeutic mAbs against Delta, BA.2, BA.4, and BA.5. The Omicron subvariants escape most antibodies but remain sensitive to bebtelovimab and cilgavimab. Consistent with their shared spike sequence, BA.4 and BA.5 display identical neutralization profiles. Sotrovimab is the most efficient at eliciting ADCC. We also analyze 121 sera from 40 immunocompromised individuals up to 6 months after infusion of Ronapreve (imdevimab + casirivimab) or Evusheld (cilgavimab + tixagevimab). Sera from Ronapreve-treated individuals do not neutralize Omicron subvariants. Evusheld-treated individuals neutralize BA.2 and BA.5, but titers are reduced. A longitudinal evaluation of sera from Evusheld-treated patients reveals a slow decay of mAb levels and neutralization, which is faster against BA.5. Our data shed light on antiviral activities of therapeutic mAbs and the duration of effectiveness of Evusheld pre-exposure prophylaxis. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36450283; pasteur-04165260; https://pasteur.hal.science/pasteur-04165260Test; https://pasteur.hal.science/pasteur-04165260/documentTest; https://pasteur.hal.science/pasteur-04165260/file/1-s2.0-S2666379122004141-main.pdfTest; PUBMED: 36450283; PUBMEDCENTRAL: PMC9706550 |
| DOI: | 10.1016/j.xcrm.2022.100850 |
| الإتاحة: | https://doi.org/10.1016/j.xcrm.2022.100850Test https://pasteur.hal.science/pasteur-04165260Test https://pasteur.hal.science/pasteur-04165260/documentTest https://pasteur.hal.science/pasteur-04165260/file/1-s2.0-S2666379122004141-main.pdfTest |
| حقوق: | http://creativecommons.org/licenses/by-nc-ndTest/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.EBDFF46E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.xcrm.2022.100850 |
|---|